ATNM - Actinium Pharma Company Long-Term Liabilities

Serving as the primary valuation tool, this Actinium Pharmaceuticals (ATNM) price chart demonstrates the dynamics of a leader in creating precision irradiation for leukemia therapy. The company's financial condition is characterized by the expenditure of existing reserves, with the indicator standing at 0.00, which fully covers product launch costs. The business relies on an academic approach and a powerful staff of radiobiologists, sustained by significant investments in scientific research and development.

Actinium Pharmaceuticals (ATNM) is actively developing its commercial infrastructure to bring radiotherapy to market, leveraging management credibility following successful clinical trials. The current value of 0.00 reflects the aggregate of obligations with maturities exceeding one year, allowing for an assessment of the balance between financial stability and debt load during business scaling via the company's long-term debt time series.